RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages

  Smallridge, Robert C ^a   Chindris, Ana Maria ^a   Asmann, Yan W ^a   Casler, John D ^a   Serie, Daniel J ^a   Reddi, Honey V ^b   Cradic, Kendall W ^b   Rivera, Michael ^b   Grebe, Stefan K ^b   Necela, Brian M ^b   Eberhardt, Norman L ^b,c   Carr, Jennifer M ^a   McIver, Bryan ^a,b,d   Copland, John A ^a   Thompson, E Aubrey ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE ANALYSIS, RNA; THYROID NEOPLASMS;

EID: 84893772701     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2792     Document Type: Article

References (55)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab. 2010;95:4197-4205.
3. O'Neill CJ, Bullock M, Chou A, et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010;148:1139-1145; discussion 1145-1136.
4. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24:6646-6656.
5. Borup R, RossingM,Henao R, et al. Molecular signatures of thyroid follicular neoplasia. Endocr Relat Cancer. 2010;17:691-708.
6. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004;23:7436-7440.
7. Rivera M, Ricarte-Filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol. 2010;23:1191-1200.
8. Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol. 2010;322:8-28.
9. Sun Z, Asmann YW, Kalari KR, et al. Integrated analysis of gene expression,CpGisland methylation, and gene copy number in breast cancer cells by deep sequencing. PLoS One. 2011;6:e17490.
10. Cradic KW, Milosevic D, Rosenberg AM, Erickson LA, McIver B, Grebe SK. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab. 2009;94:5001-5009.
11. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory- efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25.
12. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:1105-1111.
13. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139-140.
14. Asmann YW, Hossain A, Necela BM, et al. A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. Nucleic Acids Res. 2011;39: e100.
15. Asmann YW, Necela BM, Kalari KR, et al. Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer. Cancer Res. 2012;72:1921-1928.
16. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68:8673-8677.
17. Borrello MG, Alberti L, Fischer A, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA. 2005;102:14825-14830.
18. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98:15044-15049.
19. Jarzab B, Wiench M, Fujarewicz K, et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005;65:1587-1597.
20. Griffith OL, Melck A, Jones SJ, Wiseman SM. Meta-Analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol. 2006;24: 5043-5051.
21. Vierlinger K, Mansfeld MH, Koperek O, Nohammer C, Kaserer K, Leisch F. Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation. BMC Med Genomics. 2011;4:30.
22. Kim HS, Kim do H, Kim JY, et al. Microarray analysis of papillary thyroid cancers in Korean. Korean J InternMed. 2010;25:399-407.
23. Mo L, Zhang J, Shi J, et al. Human kallikrein 7 induces epithelialmesenchymal transition-like changes in prostate carcinoma cells: a role in prostate cancer invasion and progression. Anticancer Res. 2010;30:3413-3420.
24. Torregrossa L, Giannini R, Borrelli N, et al. CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. Mod Pathol. 2012;25:46-55.
25. Nunes LM, Ayres FM, Francescantonio IC, et al. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer. Hum Immunol. 2013;74:447-451.
26. Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol. 2012; 22:350-358.
27. González A, Rebmann V, LeMaoult J, Horn PA, Carosella ED, Alegre E. The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci. 2012;49:63-84.
28. Dong DD, Yie SM, Li K, et al. Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer. Hum Immunol. 2012;73:998-1004.
29. Dardano A, Rizzo R, Polini A, et al. Soluble human leukocyte antigen- g and its insertion/deletion polymorphism in papillary thyroid carcinoma: novel potential biomarkers of disease? J Clin Endocrinol Metab. 2012;97:4080-4086.
30. Oler G, Camacho CP, Hojaij FC, Michaluart P Jr, Riggins GJ, Cerutti JM. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res. 2008;14:4735-4742.
31. Bommarito A, Richiusa P, Carissimi E, et al.BRAFV600Emutation, TIMP-1 upregulation, and NF-B activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer. 2011;18: 669-685.
32. Barreyro L, Will B, Bartholdy B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012;120:1290-1298.
33. Teixeira MR. Recurrent fusion oncogenes in carcinomas. Crit Rev Oncog. 2006;12:257-271.
34. Qi M, Li Y, Liu J, et al. Morphologic features of carcinomas with recurrent gene fusions. Adv Anat Pathol. 2012;19:417-424.
35. Celestino R, Sigstad E, Løvf M, et al. Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes. Genes Chromosomes Cancer. 2012;51:1154-1164.
36. Chi HT, Ly BT, Kano Y, Tojo A, Watanabe T, Sato Y. ETV6- NTRK3as a therapeutic target of small molecule inhibitor PKC412. Biochem Biophys Res Commun. 2012;429:87-92.
37. Lannon CL, Sorensen PH. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin Cancer Biol. 2005;15:215-223.
38. Wen H, Li Y, Malek SN, et al. New fusion transcripts identified in normal karyotype acute myeloid leukemia. PLoS One. 2012;7: e51203.
39. Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436-445.
40. Lai CP, Bechberger JF, Thompson RJ, MacVicar BA, Bruzzone R, Naus CC. Tumor-suppressive effects of pannexin 1 in C6 glioma cells. Cancer Res. 2007;67:1545-1554.
41. Penuela S, Gyenis L, Ablack A, et al. Loss of pannexin 1 attenuates melanoma progression by reversion to a melanocytic phenotype. J Biol Chem. 2012;287:29184-29193.
42. Agnelli L, Forcato M, Ferrari F, et al. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res. 2011;17:7402-7412.
43. Thermes V, Candal E, Alunni A, Serin G, Bourrat F, Joly JS. Medaka simplet (FAM53B) belongs to a family of novel vertebrate genes controlling cell proliferation. Development. 2006;133:1881-1890.
44. McKinnon CM, Lygoe KA, Skelton L, Mitter R, Mellor H. The atypical Rho GTPase RhoBTB2 is required for expression of the chemokine CXCL14 in normal and cancerous epithelial cells. Oncogene. 2008;27:6856-6865.
45. Mao H, Zhang L, Yang Y, et al. RhoBTB2 (DBC2) functions as tumor suppressor via inhibiting proliferation, preventing colony formation and inducing apoptosis in breast cancer cells. Gene. 2011; 486:74-80.
46. Yu GP, Huang B, Chen GQ, Wu S, Ji Y, Shen ZY. PEBP4 gene expression and its significance in invasion and metastasis of nonsmall cell lung cancer. Tumour Biol. 2012;33:223-228.
47. Salvatico J, Kim JH, Chung IK, Muller MT. Differentiation linked regulation of telomerase activity by Makorin-1. Mol Cell Biochem. 2010;342:241-250.
48. Ko A, Shin JY, Seo J, et al. Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF. J Natl Cancer Inst. 2012;104:1660-1672.
49. Zhong B, Sallman DA, Gilvary DL, et al. Induction of clusterin by AKT-role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther. 2010;9:1831-1841.
50. Shiota M, Zardan A, Takeuchi A, et al. Clusterin mediates TGF- induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res. 2012;72:5261-5272.
51. Muzza M, Degl'Innocenti D, Colombo C, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf). 2010;72:702-708.
52. Liotti F, Visciano C, Melillo RM. Inflammation in thyroid oncogenesis. Am J Cancer Res. 2012;2:286-297.
53. French JD. Revisiting immune-based therapies for aggressive follicular cell-derived thyroid cancers. Thyroid. 2013;23:529-542.
54. Dvorkin S, Robenshtok E, Hirsch D, Strenov Y, Shimon I, Benbassat CA. Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis. J Clin Endocrinol Metab. 2013;98:2409-2414.
55. Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid. 2009;19:137-141.